NRX Pharmaceuticals Business Summary

NRx Pharmaceuticals, Inc. (NRXP) is a clinical-stage biopharmaceutical company specializing in central nervous system (CNS) disorders, specifically suicidal depression, PTSD, and chronic pain. The company has recently evolved its business model from a pure research-and-development focus to a dual-track revenue strategy. It generates immediate revenue through its subsidiary, HOPE Therapeutics, which operates a growing network of interventional psychiatry clinics providing ketamine therapy, transcranial magnetic stimulation (TMS), and digital therapeutics. Simultaneously, NRXP is advancing a high-value drug pipeline featuring NRX-101, a Breakthrough Therapy-designated treatment for bipolar depression with suicidality, and KETAFREE (NRX-100), a preservative-free intravenous ketamine formulation currently under FDA review. Within the competitive landscape, NRXP contends with established CNS-focused firms such as Sage Therapeutics, Relmada Therapeutics, Intra-Cellular Therapies, and Axsome Therapeutics, positioning itself as a niche leader in the rapid-acting antidepressant and suicide-prevention market. NRx Pharmaceuticals was co-founded by Dr. Jonathan C. Javitt and Professor Daniel C. Javitt. Dr. Jonathan Javitt, who serves as Chairman, Chief Scientist, and CEO, brings a distinguished pedigree including leadership roles in seven healthcare startups and advisory positions under four U.S. presidential administrations. The executive team was recently strengthened by the January 2026 appointment of Joseph M. Casper as Chief Operating Officer, a 35-year healthcare veteran with a background at Deloitte and Kaiser Permanente. Other key leaders include Michael Abrams as Chief Financial Officer and Dr. Riccardo Panicucci as Chief Manufacturing and Technology Officer. The company’s board of directors features notable industry figures such as Chaim Hurvitz, former President of Teva International Group, and Patrick Flynn, a founding investor. Institutional backing is provided by major shareholders including Anson Funds Management LP and Vanguard Group Inc.